Stay up-to-date with the latest in the world of psychedelics with our weekly news roundup for week 10 of 2023. Read about the latest research, policy updates, and industry developments in the rapidly growing field of psychedelic science.
Small Pharma announced further positive data from Phase IIa trial in Major Depressive Disorder
The two-staged study included a two-week blinded, randomized, placebo-controlled phase followed by a 12-week open-label phase, in which all participants received a single dose of SPL026. In January 2023 the Company reported that the Phase IIa trial met its primary endpoint with a statistically significant and clinically relevant reduction in depression symptoms at two-weeks post-dose, compared to placebo.
Statistical analysis was conducted on the MADRS open-label data. A statistically significant difference in mean total MADRS score was observed for both the one and two dose regimen groups across all open-label study timepoints (p<0.05).
Washington psychedelic policy amended to extend the state’s ongoing review of psilocybin
“It seems like the amendment to the substitute is cleaning up the bill as it left the policy committee versus changing the policy intent of what came out of the policy committee,” Ways and Means Committee Chair Sen. Christine Rolfes (D) observed before the vote.
One noteworthy change under Robinson’s amendment is that it gets rid of Keiser’s proposal to establish a state registry of adults who express interest in using psilocybin. Critics said many people wouldn’t want to put their personal information on a government log that tracks those who may want to try what is still a federally illegal substance.
After all the changes, what was once an 81-page bill to legalize psilocybin services for adults is now an eight-page proposal to form a psilocybin task force.
Nevada lawmakers introduced a bill to legalize magic mushrooms and study effects of ecstasy
As written, Senate Bill 242 would legalize fungi, containing psilocybin or psilocin, in amounts smaller than 4 ounces. The naturally occurring compounds create a hallucinogenic effect, leading to their “magic” moniker. The legalization would only apply to people 18 and older.
The bill would also allow a research facility to petition the state to study the effects of MDMA, also known as ecstasy, and magic mushrooms, to treat mental health conditions, such as depression and anxiety.
The Department of Justice said there is “no evidence that users may become physically dependent on psilocybin,” but that its misuse can lead to “an inability to discern fantasy from reality” and panic.
Missouri lawmakers approved a bill to promote research into the therapeutic potential of certain psychedelics
The researchers would need to explore the potential therapeutic benefits of the psychedelics on post-traumatic stress disorder (PTSD), severe depression, substance misuse disorder and people in end-of-life care.
The department would be required to carry out a clinical trial involving psilocybin, review the existing scientific literature on the medical potential of these substances and assess “access that patients have to MDMA, psilocybin, and ketamine for such treatment.”
Psychedelic Market Update – March 6th – 8th
| Ticker | Current Price | Week To Date | Year to Date |
| $MDMA | 0.215 | 59% | 760.00% |
| $CMND | 4.25 | 39.80% | 34.49% |
| $CYBN | 0.413 | -7.19% | 39.06% |
| $DRUG | 0.535 | -12.30% | -27.70% |
| $MNMD | 3.03 | -12.43% | 37.73% |
| $MMED | 4.15 | -12.63% | 39.26% |
| $AGN.CN | 0.54 | -15.62% | 0.93% |
| $ATAI | 1.25 | -19.87% | -53% |
| $GHRS | 8.72 | -20.15% | -10.29% |
| $AWKN | 0.39 | -22.00% | 30.00% |
